Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Bulk Drug Intermediates >  TAK-438

TAK-438

Basic information Safety Related Supplier
TAK-438 Basic information
TAK-438 Usage And Synthesis
  • DescriptionVonoprazan fumarate (Takecab®), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs.
  • Chemical SynthesisCommercially available 2-fluoroacetophenone (283) was brominated to yield a-bromo-acetophenone derivative 284. This compound was treated with ethyl 2-cyanoacetate (285) under basic conditions to provide ketoester 286 in essentially quantitative yield. Next, intramolecular condensation of 286 upon treatment of 4 M HCl furnished the tri-substituted pyrrole 287 in 53% yield. Reduction of the chloride under hydrogenolytic conditions facilitated arrival at pyrrole 288, albeit in just 18% yield. Subsequent diisobutylaluminium hydride (DIBAL) reduction, followed by the oxidation with tetrapropylammonium perruthenate (TPAP) and 4-methylmorpholine N-oxide (NMMO) afforded the corresponding aldehyde 290 in 60% yield across the 2 steps. Next, N-pyrrole substitution with pyridine- 3-sulfonyl chloride 291 gave rise to N-sulfonylpyrrole 292 in 82% yield. Reductive amination of 292 afforded amine 293, which was treated with fumaric acid (294) via co-crystallization to provide vonoprazan fumarate (XXXVI) in 74% for the two steps.

TAK-438(1260141-27-2)Related Product Information
TAK-438SupplierMore
  • Company Name:Shandong yuhe medicine technology co., ltd Gold
  • Tel:15726139876 1572-6139876-
  • Email:1345456643@qq.com
  •  
  • Company Name:Beijing Zhongshuo Pharmaceutical Technology Development Co., Ltd Gold
  • Tel:13801208576 010-64430626-
  • Email:sales@chinazhongshuo.com;sales.1@chinazhongshuo.com
  •  
  • Company Name:Bayee Biotech (Anqing) Co., Ltd. Gold
  • Tel:18917961636 0556-5032306
  • Email:sylvia.lee@bayeebio.com
  •  
  • Company Name:Guangzhou Isun Pharmaceutical Co., Ltd Gold
  • Tel:18927568969 020-39119399-
  • Email:isunpharm@qq.com
  •  
  • Company Name:Jinan Baozhao Pharmaceutical Technology Co., Ltd. Gold
  • Tel:0531-86397156
  • Email:baozhaopharm@163.com
  •